CEL-SCI Corporation, a clinical stage cancer immunotherapy company, has successfully closed its underwritten public offering of 2,000,000 shares of common stock, priced at $2.50 per share. The offering generated total gross proceeds of $5 million, prior to the deduction of underwriting discounts and other related expenses. The company has also granted underwriters a 45-day option to purchase an additional 190,000 shares to address over-allotments. The funds raised are intended to support the continued development of Multikine, as well as general corporate purposes and working capital. ThinkEquity served as the sole book-running manager for the offering.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CEL-SCI Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20250523121657) on May 23, 2025, and is solely responsible for the information contained therein.